ide-cel 早期复发后 BCMA 靶向双特异性抗体治疗结局不佳:一项法国真实世界研究 Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study. PubMed 2026/02/24 发表Blood AdvQ1 · IF 7.7(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤
双特异性抗体在多发性骨髓瘤中的演进 The evolution of bispecific antibodies in multiple myeloma. PubMed 2026/02/01 发表Chin Clin OncolQ3 · IF 2.7(JCR 2025) 靶点:CD20靶点:CD38靶点:BCMA技术:双特异性抗体多发性骨髓瘤B细胞淋巴瘤淋巴瘤
浆细胞疾病细胞免疫治疗的 2025 年更新 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. PubMed 2025/12/23 发表Turk J HaematolQ3 · IF 1.6(JCR 2025) 靶点:CD19靶点:BCMA靶点:GPRC5D技术:CAR-T技术:CAR-NK技术:基因编辑
多发性骨髓瘤中的双特异性抗体:通过合理联合治疗最大化潜力 Bispecific antibodies in multiple myeloma: maximizing potential through rational combination therapies. PubMed 2025/10/30 发表Blood RevQ1 · IF 7.2(JCR 2025) 靶点:BCMA靶点:GPRC5D靶点:FcRH5技术:CAR-T技术:双特异性抗体多发性骨髓瘤
我们到了吗?多发性骨髓瘤中的 CAR-T 治疗 Are we there yet? CAR-T therapy in multiple myeloma. PubMed 2024/11/19 发表Br J HaematolQ2 · IF 3.6(JCR 2025) 靶点:BCMA靶点:GPRC5D靶点:FcRH5技术:CAR-T多发性骨髓瘤地区:欧洲
仅仅是触及表面:靶向细胞膜蛋白的多发性骨髓瘤新型治疗方法 Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. PubMed 2024/07/03 发表Nat Rev Clin OncolQ1 · IF 94.6(JCR 2025) 靶点:BCMA靶点:GPRC5D靶点:FcRH5技术:CAR-T技术:双特异性抗体多发性骨髓瘤
双特异性抗体治疗复发/难治性多发性骨髓瘤:更新与未来展望 Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives. PubMed 2024/04/10 发表Front OncolQ2 · IF 3.4(JCR 2025) 靶点:BCMA靶点:GPRC5D靶点:FcRH5技术:NK 细胞技术:双特异性抗体多发性骨髓瘤
BCMA 之外的多发性骨髓瘤 T 细胞重定向双特异性与三特异性抗体 T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA. PubMed 2023/07/24 发表Curr Opin OncolQ3 · IF 2.4(JCR 2025) 靶点:BCMA靶点:GPRC5D靶点:FcRH5技术:CAR-T技术:双特异性抗体多发性骨髓瘤
多发性骨髓瘤靶向免疫治疗新前沿的潜力抗原 Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. PubMed 2021/12/06 发表Cancers (Basel)Q2 · IF 4.8(JCR 2025) 靶点:CD38靶点:BCMA靶点:GPRC5D技术:CAR-T技术:双特异性抗体多发性骨髓瘤